Skip to main content
Comparison

Tirzepatide vs Semaglutide: Complete Comparison

Tirzepatide produced greater average weight reduction than semaglutide in a direct obesity trial at the doses studied. Treatment choice also depends on the specific product and indication, health history, tolerability and access.

By the Peptide Dossier Editorial TeamUpdated How we source

At a Glance: Side-by-Side Comparison

Products and trial findings have different indications, formulations and populations. Trial doses are context, not a personal dosing plan.
FactorTirzepatide (Mounjaro/Zepbound)Semaglutide (Ozempic/Wegovy)
Receptor activityGIP and GLP-1 receptor agonistGLP-1 receptor agonist
DeveloperEli LillyNovo Nordisk
Product selectionMounjaro and Zepbound have distinct labeled indicationsOzempic and Wegovy have distinct labeled indications and formulations
Direct obesity trialSURMOUNT-5: −20.2% mean weight change at 72 weeks (10 or 15 mg weekly)SURMOUNT-5: −13.7% at 72 weeks (1.7 or 2.4 mg weekly)
AdministrationWeekly subcutaneous injectionWeekly injection or daily oral formulations, depending on product
Dose selectionInitiation, escalation and maintenance are indication- and response-specificProduct-specific initiation and maintenance; oral and injection doses are not interchangeable
Gastrointestinal effectsCommon; individual tolerability mattersCommon; individual tolerability matters
Cardiovascular evidenceSURPASS-CVOT: noninferior to dulaglutide for MACE in type 2 diabetes with established cardiovascular diseaseSELECT: fewer MACE than placebo in established cardiovascular disease with overweight/obesity without diabetes
Access and priceVerify the actual prescription, coverage and recurring patient costVerify the actual prescription, coverage and recurring patient cost

Mechanism: Why Dual vs Single Matters

Tirzepatide activates GIP and GLP-1 receptors; semaglutide activates GLP-1 receptors. Both affect appetite and glucose regulation. Their labels describe glucose-dependent effects on insulin and glucagon and delayed gastric emptying. Receptor activity helps explain the research rationale, but receptor count alone does not predict a person’s response or prove a tolerability advantage.

The comparative trials below test complete medicines and regimens, rather than isolating the contribution of GIP or establishing that GIP protects against nausea. See the current Mounjaro label and Wegovy label for product pharmacology and instructions.

Weight Loss Results: The Numbers

SURMOUNT-5 is the direct obesity comparison: This open-label, Lilly-funded phase 3b trial randomized 751 adults with obesity without type 2 diabetes to maximum tolerated weekly tirzepatide 10 or 15 mg or semaglutide 1.7 or 2.4 mg. At 72 weeks, mean percentage weight change was −20.2% versus −13.7%, respectively. Waist circumference also fell more with tirzepatide. These are group averages from the studied regimens, not a forecast for a particular starting weight. The trial did not test current Wegovy 7.2 mg or oral Wegovy. Read the original SURMOUNT-5 report.

The separate pivotal trials remain useful: In SURMOUNT-1, 2,539 adults with obesity or overweight and a weight-related complication, without diabetes, were studied for 72 weeks. Treatment-regimen estimates were −15.0%, −19.5% and −20.9% with tirzepatide 5, 10 and 15 mg, versus −3.1% with placebo. In STEP 1, 1,961 adults without diabetes were studied for 68 weeks; semaglutide 2.4 mg produced −14.9% versus −2.4% with placebo under its treatment-policy analysis. These different trials should not be used as a matched comparison or mixed with on-treatment estimates. SURMOUNT-1; STEP 1.

SURPASS-2 studied 1,879 adults with type 2 diabetes taking metformin for 40 weeks. Weekly tirzepatide 5/10/15 mg produced larger average HbA1c and weight reductions than semaglutide 1 mg. HbA1c changes were −2.01/−2.24/−2.30 versus −1.86 percentage points. This is a useful direct diabetes comparison, not a comparison against every semaglutide dose or formulation.

Side Effects: How They Compare

Tolerability: Gastrointestinal events were the most common adverse events in both SURMOUNT-5 groups, mostly mild to moderate and concentrated during escalation. Percentages from different obesity and diabetes trials cannot establish which drug causes less nausea per pound lost. Neither greater average weight reduction nor earlier approval proves a universal safety advantage.

Important product warnings: Both medicines carry thyroid C-cell tumor boxed warnings based on rodent findings; human relevance is unknown. A personal or family history of medullary thyroid carcinoma or MEN2 is a contraindication, as is serious hypersensitivity to the relevant medicine. Labels also address pancreatitis, gallbladder disease, severe gastrointestinal reactions, kidney injury related to volume depletion, aspiration around anesthesia, and hypoglycemia with insulin or insulin secretagogues. Medical history, other medicines and the exact formulation matter. Read the Zepbound and Wegovy warnings with the prescriber.

Severe or persistent abdominal pain, repeated vomiting with inability to retain fluids, marked dehydration or a serious allergic reaction needs prompt assessment. Suspected pancreatitis calls for stopping the drug and evaluation; severe allergic symptoms require urgent care. Significant gastroparesis, retinopathy, pregnancy plans and other medicines affect selection. Semaglutide labels advise stopping at least two months before a planned pregnancy; tirzepatide has a separate four-week oral-hormonal-contraception precaution after initiation and each escalation.

Body composition: Weight reduction can include both fat and lean tissue. DXA lean mass is not a direct measure of skeletal muscle strength or function, and a fixed fat-to-lean loss ratio should not be assigned to every person or both medicines. Nutrition and resistance activity can be discussed in the context of age, intake, function and health conditions; weight-loss percentages alone do not establish comparative muscle outcomes.

Cardiovascular outcomes: SELECT randomized 17,604 adults with established cardiovascular disease and overweight or obesity without diabetes. Semaglutide 2.4 mg reduced major adverse cardiovascular events versus placebo (6.5% versus 8.0%; hazard ratio 0.80) over a mean 39.8 months of follow-up. SURPASS-CVOT is now completed: in adults with type 2 diabetes and established cardiovascular disease, tirzepatide was noninferior to dulaglutide for MACE (hazard ratio 0.92; 95.3% CI 0.83–1.01); superiority was not established. These different comparators and populations support specific benefits, not a cardiovascular ranking between tirzepatide and semaglutide. SELECT; Mounjaro label, section 14.6.

Who Should Choose What?

Start with the intended indication and exact product. Zepbound has adult weight-management and obstructive sleep apnea indications with different maintenance-dose options. Mounjaro has type 2 diabetes indications, including glycemic control in patients aged 10 years and older and a cardiovascular indication in specified adults. Wegovy has weight-management and cardiovascular indications with formulation-specific populations and instructions. These brand labels are not interchangeable eligibility checklists.

For weight management, the greater average reduction in SURMOUNT-5 is a meaningful reason to discuss tirzepatide. Semaglutide remains an effective option, with its own outcome evidence and oral as well as injectable Wegovy formulations. Current Wegovy labeling also includes a 7.2 mg injection option for selected adults who tolerate 2.4 mg for at least four weeks and need additional weight reduction; SURMOUNT-5 did not compare it. A milligram number cannot be converted between these medicines.

Discuss contraindications, pregnancy plans, other medicines, prior response, tolerability and sustainable access with the clinician. Tirzepatide labeling advises a nonoral contraceptive method or added barrier contraception for four weeks after initiation and each dose increase when using oral hormonal contraception. Do not choose tirzepatide on an unproven promise of less nausea, escalate to chase a result, or combine it with another GLP-1 medicine.

Compare a current itemized quote for the exact product, dose, device and prescription indication. Original estimates of roughly $800–$1,500 monthly for branded injections were historical examples, not current offers. Coverage, deductibles, quantity limits and manufacturer-program eligibility vary; commercial savings cards generally have exclusions and do not guarantee a $25 copay or uninsured access. Medicare/Medicaid decisions depend on the covered indication and applicable rules rather than a blanket exclusion of every use. For broader online weight-management care, SurpassMD describes its program and assessment process.

For cost, obtain the actual recurring quote and verify insurance, assistance eligibility and dispensing terms. No fixed price comparison applies to everyone. Compounded products are not FDA-approved generics; individual medical need, applicable compounding conditions and quality are separate issues from branded trial outcomes. FDA explains the limits and concerns for unapproved GLP-1 products.

Product-Specific Starting and Escalation Instructions

For weekly Ozempic injection, the label starts at 0.25 mg for four weeks, then 0.5 mg; increases to 1 mg and then 2 mg require at least four weeks at the preceding dose when additional glycemic control is needed. The 0.25-mg dose is for initiation. Ozempic does not have labeled 1.5-, 1.7- or 2.4-mg injection steps; the CKD outcome indication has a specified 1-mg maintenance instruction.

Weekly Wegovy injection generally escalates at four-week stages from 0.25 through 0.5, 1 and 1.7 mg toward the indication-specific maintenance dose; tolerance can justify delay. The current label also includes a conditional 7.2-mg adult weight-management option after at least four tolerated weeks at 2.4 mg. Daily oral Wegovy follows its own 30-day steps toward 25 mg. These are distinct schedules, not interchangeable milligrams.

Mounjaro starts at 2.5 mg once weekly; increases in 2.5-mg steps require additional glycemic control and at least four weeks at the current dose. Zepbound starts at 2.5 mg weekly for four weeks, then 5 mg; later increases require at least four weeks at the current dose, considering response and tolerability. Adult maximum is 15 mg; Mounjaro’s pediatric maximum is 10 mg. Zepbound weight-management maintenance doses are 5, 10 or 15 mg, whereas its OSA maintenance doses are 10 or 15 mg. A maximum is not a target for everyone.

These are labeled product distinctions, not a conversion between medicines or a personal prescription. Read the Ozempic, Wegovy, Mounjaro and Zepbound instructions for the supplied presentation.

Switching and Changes Over Time

Switching may be reasonable for response, tolerability or access, but there is no universal milligram conversion or 7–14-day washout. The prescriber needs the actual product, last dose, current symptoms, other glucose medicines and any interruption. Do not overlap GLP-1 products or automatically restart at a high dose. Product-specific labeled transitions do not validate alternating brands monthly or every proposed conversion.

Trial averages describe a population at a specified follow-up, not a week-by-week forecast. Appetite, glucose and weight can change on different schedules; escalation, adherence, diabetes, tolerability and other treatment affect response. A starting-weight example cannot predict a fixed number of pounds by week 4, 12 or 24. Reassess the actual trajectory rather than escalate to meet a promised calendar.

STEP 4 randomized selected adults after a 20-week semaglutide run-in: over the subsequent 48 weeks, continuing treatment produced further loss while switching to placebo led to regain. SURMOUNT-4 similarly found maintenance/further loss with continued tirzepatide and regain after withdrawal following its run-in. These selected randomized-withdrawal results support ongoing management, but do not mean everyone regains the same amount or that lifestyle cannot help.

What Comes Next: Retatrutide

Retatrutide is an investigational GIP, GLP-1 and glucagon receptor agonist. In the published 80-week phase 3 trial in 2,339 adults with obesity or overweight and a complication without type 2 diabetes, treatment-regimen estimates of mean weight change were −17.6%, −23.7% and −25.0% with 4, 9 and 12 mg, versus −3.9% with placebo. These favorable findings use a different analysis from larger on-treatment headlines and do not establish superiority to either medicine in a head-to-head trial. Read the original phase 3 report.

Retatrutide remains unapproved. FDA states that it is not a component of an FDA-approved drug and cannot be used in compounding under federal law. Research results do not make online “research” products approved treatment options.

Frequently Asked Questions

SURPASS-2 showed larger average HbA1c reductions with tirzepatide 5/10/15 mg than semaglutide 1 mg in adults taking metformin at 40 weeks. This does not compare every semaglutide dose or settle individual cardiovascular, kidney or tolerability priorities.

Zepbound has adult weight-management and obesity-related moderate-to-severe OSA indications. Mounjaro contains tirzepatide but has diabetes and specified adult cardiovascular indications; an ingredient’s approval does not transfer automatically to every brand.

In SURMOUNT-5, adults with obesity without type 2 diabetes assigned to maximum tolerated weekly tirzepatide 10 or 15 mg lost an average 20.2% at 72 weeks, compared with 13.7% with semaglutide 1.7 or 2.4 mg. This direct trial supports greater average weight reduction with tirzepatide at those doses. It does not compare current higher-dose or oral Wegovy formulations, guarantee an individual result, or settle every treatment decision.

No universal safety winner is established. Both have important contraindications and warnings as well as gastrointestinal adverse effects. Cardiovascular trials answer different questions: SELECT tested semaglutide against placebo in adults with established cardiovascular disease and overweight or obesity without diabetes; SURPASS-CVOT tested tirzepatide against dulaglutide in adults with type 2 diabetes and established cardiovascular disease. Neither directly ranks these two drugs for overall safety.

A clinician can consider a switch after reviewing the indication, current dose, last dose, glucose control, other medicines and tolerability. There is no validated milligram-for-milligram conversion or universal switch schedule. Do not overlap or independently substitute these medicines; the clinician should provide the new prescription and timing instructions.

Tirzepatide activates GIP and GLP-1 receptors, whereas semaglutide activates GLP-1 receptors. This is an important biological difference, and direct trials have favored tirzepatide for average weight reduction at the regimens studied. Those trials do not isolate how much benefit comes from each receptor or prove that GIP activation prevents nausea. Results depend on the product, dose, population and endpoint.

Gastrointestinal events were the most common adverse events with both medicines in SURMOUNT-5, generally mild to moderate and occurring mainly during dose escalation. That trial does not establish a general safety or tolerability winner. Comparing nausea percentages from separate obesity and diabetes trials can mislead because doses, populations and methods differ. Individual tolerability requires follow-up.

Compare the actual recurring patient price for the prescribed product, dose and dispensing arrangement, including insurance eligibility and any assistance conditions. A list price or introductory offer does not establish what someone will pay long term. Compounded products are not FDA-approved generics; their regulatory eligibility and quality require separate assessment.

Disclaimer: This comparison is for informational purposes only. Both tirzepatide and semaglutide are prescription medications that should only be used under medical supervision. Individual results vary significantly. Consult your healthcare provider to determine which medication, if any, is appropriate for your specific situation.

Read the study question before comparing outcomes

These studies differ in participants, run-in treatment, behavioral support and endpoints. Side-by-side presentation is indirect evidence, not a pooled efficacy ranking.

Weight change: study design and applicability
StudyCompoundPopulationDesign / follow-upEndpointLimits
STEP 1SemaglutideAdults with overweight/obesity without diabetesRandomized, double-blind, placebo-controlled; 68 weeksPercent change in body weight and achieving at least 5% lossLifestyle intervention accompanied both groups; this is not a head-to-head drug comparison.
STEP 2SemaglutideAdults with overweight/obesity and type 2 diabetesRandomized, double-blind, double-dummy, placebo-controlled; 68 weeksPercent change in body weight and achieving at least 5% lossDiabetes population; results should not be substituted for STEP 1 or compared as if randomized across trials.
STEP 3SemaglutideAdults with overweight/obesity without diabetesRandomized, double-blind, placebo-controlled, with intensive behavioral therapy; 68 weeksPercent change in body weight and achieving at least 5% lossInitial low-calorie diet and intensive behavioral support limit comparisons with less intensive programs.
SURMOUNT-1TirzepatideAdults with overweight/obesity without diabetesRandomized, double-blind, placebo-controlled; 72 weeksPercent change in body weight and achieving at least 5% lossSeparate treatment groups and lifestyle support; do not compare raw percentages with another trial as a randomized contrast.
SURMOUNT-2TirzepatideAdults with overweight/obesity and type 2 diabetesRandomized, double-blind, placebo-controlled; 72 weeksPercent change in body weight and achieving at least 5% lossDiabetes population and specified study regimens; not interchangeable with SURMOUNT-1.
SURMOUNT-3TirzepatideAdults without diabetes who lost at least 5% during intensive lifestyle interventionRandomized, double-blind, placebo-controlled after lifestyle lead-in; 12-week lead-in; 72-week randomized treatmentWeight change after randomization and achieving at least 5% further lossSelected lifestyle responders; total change from lead-in and change after randomization are different quantities.

For the direct comparison, read the primary paper and its adverse-event and analysis sections together. No treatment choice is inferred from this matrix.